Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23260652 | 0.83 | USP2 (0.43) | USP2ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL18481147 | 0.78 | ALDH1A1 (0.42) | USP2ALDH1A1KDM4EGLASMN1; SMN2 | |
| SCHEMBL1385192 | 0.78 | MEN1 (0.39) | ALDH1A1MAPTTSHRANPEPLMNA | |
| SCHEMBL23892766 | 0.77 | USP2 (0.62) | USP2ALDH1A1HSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL18735945 | 0.74 | MGLL (0.38) | ALDH1A1KDM4EMAPTTSHRPHGDH | |
| SCHEMBL12039413 | 0.73 | — | — | |
| SCHEMBL24079207 | 0.73 | CHRM5 (0.44) | ALDH1A1HSD17B10RECQLANPEPPHGDH | |
| SCHEMBL24176315 | 0.72 | USP2 (0.42) | USP2ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL14483902 | 0.72 | USP2 (0.56) | USP2ALDH1A1KDM4EHSD17B10ALOX15 | |
| SCHEMBL20968773 | 0.70 | USP2 (0.48) | USP2ALDH1A1KDM4EHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040318-A2 | COMPOSITIONS, METHODS AND KITS FOR DETECTING MELANOMA AND MARGINS OF MELANOMA | UNIVERSITY OF MIAMI (US) | 2012-03-29 | — | — | WO | claimed |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2023-04-25 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-10815482-B2 | Chiral design | WAVE LIFE SCIENCES LTD. (SG) | 2020-10-27 | — | — | US | disclosed |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | US | disclosed |
| US-20190106696-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2019-04-11 | — | — | US | disclosed |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| WO-2012040318-A2 | COMPOSITIONS, METHODS AND KITS FOR DETECTING MELANOMA AND MARGINS OF MELANOMA | UNIVERSITY OF MIAMI (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | HDAC5, HDAC2, HDAC8 | USP2 1846/4885ALDH1A1 942/4885KDM4E 428/4885 |
| US-20200299692-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | USP2 3575/4885ALDH1A1 3613/4885KDM4E 2911/4885 |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | HDAC5, HDAC2, HDAC8 | USP2 1846/4885ALDH1A1 942/4885KDM4E 428/4885 |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | USP2 3443/4885ALDH1A1 645/4885KDM4E 2185/4885 |
| US-11634710-B2 | Oligonucleotide compositions and methods thereof | RBM17, HNRNPA2B1, HNRNPA1 | USP2 3575/4885ALDH1A1 3613/4885KDM4E 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.